

# Eventide Healthcare & Life Sciences Fund

## Class A (ETAHX)

Annual Shareholder Report - June 30, 2024



### Fund Overview

This annual shareholder report contains important information about Eventide Healthcare & Life Sciences Fund for the period of July 1, 2023 to June 30, 2024. You can find additional information about the Fund at <https://www.eventidefunds.com>. You can also request this information by contacting us at 1-877-771-3836. **This report describes changes to the Fund that occurred during the reporting period.**

### What were the Fund's costs for the last year?


(based on a hypothetical \$10,000 investment)

Class Name	Costs of a \$10,000 investment	Costs paid as a percentage of a \$10,000 investment
Class A	\$157	1.57%

### How did the Fund perform during the reporting period?

As the fiscal year began, the market faced the implications of "higher for longer" interest rates. With hopes for rate cuts diminishing, Biotechnology underperformed, though the disruption did offer investors attractive entry points. We are confident in the Fund's investment process and the Healthcare sector's remarkable innovation in diabetes, Alzheimer's, cancer, and other conditions of unmet need. Given the scarcity of capital, the Fund has been overweight those in later development stages, especially in oncology and immunology. We believe the Fund is strategically aligned to leverage the Biotech's anticipated growth. Despite recent underperformance relative to the Fund's benchmark, we believe our focus on companies with high likelihood of clinical and commercial success positions the Fund well for long-term value creation.

### How has the Fund performed over the last ten years?




The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares. In connection with new SEC Rules on shareholder reporting, the Fund's performance information above is compared with a broad-based benchmark, Bloomberg US 3000 Equal Weight Total Return Index, which represents the overall domestic equity market. In addition, the strategy benchmark, S&P Biotechnology Select Industry Total Return Index, is included as the adviser believes it is more representative of the fund's investment universe.

Fund Statistics	
Net Assets	\$1,439,915,749
Number of Portfolio Holdings	94
Advisory Fee	\$17,506,668
Portfolio Turnover	71%


	1 Year	5 Years	10 Years
Eventide Healthcare & Life Sciences Fund - Class A			
Without Load	-9.78%	1.99%	9.38%
With Load	-14.96%	0.78%	8.73%
S&P Biotechnology Select Industry Total Return Index	11.93%	1.28%	6.28%
Bloomberg US 3000 Equal Weight Total Return Index	6.75%	7.03%	6.85%

## What did the Fund invest in?

### Industry Weighting (% of net assets)



### Asset Weighting (% of total investments)



### Top 10 Holdings\* (% of net assets)

Holding Name	% of Net Assets
Celldex Therapeutics, Inc.	4.0%
Mirum Pharmaceuticals, Inc.	4.0%
Vaxcyte, Inc.	3.9%
Insmed, Inc.	3.1%
Aura Biosciences, Inc.	3.0%
Guardant Health, Inc.	2.9%
Collegium Pharmaceutical, Inc.	2.9%
Axsome Therapeutics, Inc.	2.8%
Sarepta Therapeutics, Inc.	2.5%
Lexeo Therapeutics, Inc.	2.3%

\* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

## Material Fund Changes

This is a summary of certain changes to the Fund since July 1, 2023. For more complete information, you may review the Fund's next prospectus, which we expect to be available by November 1, 2024 at <https://www.eventidefunds.com/prospectus> or upon request at 1-877-771-EVEN (3836). As of January 2024, Dr. Kyle Rasbach is no longer a portfolio manager of the Fund.



## Eventide Healthcare & Life Sciences Fund - Class A (ETAHX)

Annual Shareholder Report - June 30, 2024

## Where can I find additional information about the Fund?

Additional information is available on the Fund's website (<https://www.eventidefunds.com>), including its:

- Prospectus
- Financial information
- Holdings
- Proxy voting information

# Eventide Healthcare & Life Sciences Fund

## Class C (ETCHX)

Annual Shareholder Report - June 30, 2024



### Fund Overview

This annual shareholder report contains important information about Eventide Healthcare & Life Sciences Fund for the period of July 1, 2023 to June 30, 2024. You can find additional information about the Fund at <https://www.eventidefunds.com>. You can also request this information by contacting us at 1-877-771-3836. **This report describes changes to the Fund that occurred during the reporting period.**

### What were the Fund's costs for the last year?


(based on a hypothetical \$10,000 investment)

Class Name	Costs of a \$10,000 investment	Costs paid as a percentage of a \$10,000 investment
Class C	\$232	2.32%

### How did the Fund perform during the reporting period?

As the fiscal year began, the market faced the implications of "higher for longer" interest rates. With hopes for rate cuts diminishing, Biotechnology underperformed, though the disruption did offer investors attractive entry points. We are confident in the Fund's investment process and the Healthcare sector's remarkable innovation in diabetes, Alzheimer's, cancer, and other conditions of unmet need. Given the scarcity of capital, the Fund has been overweight those in later development stages, especially in oncology and immunology. We believe the Fund is strategically aligned to leverage the Biotech's anticipated growth. Despite recent underperformance relative to the Fund's benchmark, we believe our focus on companies with high likelihood of clinical and commercial success positions the Fund well for long-term value creation.

### How has the Fund performed over the last ten years?




The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares. In connection with new SEC Rules on shareholder reporting, the Fund's performance information above is compared with a broad-based benchmark, Bloomberg US 3000 Equal Weight Total Return Index, which represents the overall domestic equity market. In addition, the strategy benchmark, S&P Biotechnology Select Industry Total Return Index, is included as the adviser believes it is more representative of the fund's investment universe.

Fund Statistics	
Net Assets	\$1,439,915,749
Number of Portfolio Holdings	94
Advisory Fee	\$17,506,668
Portfolio Turnover	71%


	1 Year	5 Years	10 Years
Eventide Healthcare & Life Sciences Fund - Class C	-10.44%	1.22%	8.57%
S&P Biotechnology Select Industry Total Return Index	11.93%	1.28%	6.28%
Bloomberg US 3000 Equal Weight Total Return Index	6.75%	7.03%	6.85%

## What did the Fund invest in?

### Industry Weighting (% of net assets)



### Asset Weighting (% of total investments)



### Top 10 Holdings\* (% of net assets)

Holding Name	% of Net Assets
Celldex Therapeutics, Inc.	4.0%
Mirum Pharmaceuticals, Inc.	4.0%
Vaxcyte, Inc.	3.9%
Insmed, Inc.	3.1%
Aura Biosciences, Inc.	3.0%
Guardant Health, Inc.	2.9%
Collegium Pharmaceutical, Inc.	2.9%
Axsome Therapeutics, Inc.	2.8%
Sarepta Therapeutics, Inc.	2.5%
Lexeo Therapeutics, Inc.	2.3%

\* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

## Material Fund Changes

This is a summary of certain changes to the Fund since July 1, 2023. For more complete information, you may review the Fund's next prospectus, which we expect to be available by November 1, 2024 at <https://www.eventidefunds.com/prospectus> or upon request at 1-877-771-EVEN (3836). As of January 2024, Dr. Kyle Rasbach is no longer a portfolio manager of the Fund.



## Eventide Healthcare & Life Sciences Fund - Class C (ETCHX )

Annual Shareholder Report - June 30, 2024

## Where can I find additional information about the Fund?

Additional information is available on the Fund's website ( <https://www.eventidefunds.com> ), including its:

- Prospectus
- Financial information
- Holdings
- Proxy voting information

# Eventide Healthcare & Life Sciences Fund

## Class I (ETIHX )

Annual Shareholder Report - June 30, 2024



### Fund Overview

This annual shareholder report contains important information about Eventide Healthcare & Life Sciences Fund for the period of July 1, 2023 to June 30, 2024. You can find additional information about the Fund at <https://www.eventidefunds.com>. You can also request this information by contacting us at 1-877-771-3836. **This report describes changes to the Fund that occurred during the reporting period.**

### What were the Fund's costs for the last year?


(based on a hypothetical \$10,000 investment)

Class Name	Costs of a \$10,000 investment	Costs paid as a percentage of a \$10,000 investment
Class I	\$132	1.32%

### How did the Fund perform during the reporting period?

As the fiscal year began, the market faced the implications of "higher for longer" interest rates. With hopes for rate cuts diminishing, Biotechnology underperformed, though the disruption did offer investors attractive entry points. We are confident in the Fund's investment process and the Healthcare sector's remarkable innovation in diabetes, Alzheimer's, cancer, and other conditions of unmet need. Given the scarcity of capital, the Fund has been overweight those in later development stages, especially in oncology and immunology. We believe the Fund is strategically aligned to leverage the Biotech's anticipated growth. Despite recent underperformance relative to the Fund's benchmark, we believe our focus on companies with high likelihood of clinical and commercial success positions the Fund well for long-term value creation.

### How has the Fund performed over the last ten years?




The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares. In connection with new SEC Rules on shareholder reporting, the Fund's performance information above is compared with a broad-based benchmark, Bloomberg US 3000 Equal Weight Total Return Index, which represents the overall domestic equity market. In addition, the strategy benchmark, S&P Biotechnology Select Industry Total Return Index, is included as the adviser believes it is more representative of the fund's investment universe.

### Average Annual Total Returns


Fund Statistics	1 Year	5 Years	10 Years
Net Assets	\$1,439,915,749		
Number of Portfolio Holdings	94		
Advisory Fee	\$17,506,668		
Portfolio Turnover	71%		
Eventide Healthcare & Life Sciences Fund - Class I	-9.58%	2.23%	9.66%
S&P Biotechnology Select Industry Total Return Index	11.93%	1.28%	6.28%
Bloomberg US 3000 Equal Weight Total Return Index	6.75%	7.03%	6.85%

## What did the Fund invest in?

### Industry Weighting (% of net assets)



### Asset Weighting (% of total investments)



### Top 10 Holdings\* (% of net assets)

Holding Name	% of Net Assets
Celldex Therapeutics, Inc.	4.0%
Mirum Pharmaceuticals, Inc.	4.0%
Vaxcyte, Inc.	3.9%
Insmed, Inc.	3.1%
Aura Biosciences, Inc.	3.0%
Guardant Health, Inc.	2.9%
Collegium Pharmaceutical, Inc.	2.9%
Axsome Therapeutics, Inc.	2.8%
Sarepta Therapeutics, Inc.	2.5%
Lexeo Therapeutics, Inc.	2.3%

\* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

## Material Fund Changes

This is a summary of certain changes to the Fund since July 1, 2023. For more complete information, you may review the Fund's next prospectus, which we expect to be available by November 1, 2024 at <https://www.eventidefunds.com/prospectus> or upon request at 1-877-771-EVEN (3836). As of January 2024, Dr. Kyle Rasbach is no longer a portfolio manager of the Fund.



## Eventide Healthcare & Life Sciences Fund - Class I (ETIHX)

Annual Shareholder Report - June 30, 2024

## Where can I find additional information about the Fund?

Additional information is available on the Fund's website ( <https://www.eventidefunds.com> ), including its:

- Prospectus
- Financial information
- Holdings
- Proxy voting information

# Eventide Healthcare & Life Sciences Fund

## Class N (ETNHX)

Annual Shareholder Report - June 30, 2024



### Fund Overview

This annual shareholder report contains important information about Eventide Healthcare & Life Sciences Fund for the period of July 1, 2023 to June 30, 2024. You can find additional information about the Fund at <https://www.eventidefunds.com>. You can also request this information by contacting us at 1-877-771-3836. **This report describes changes to the Fund that occurred during the reporting period.**

### What were the Fund's costs for the last year?


(based on a hypothetical \$10,000 investment)

Class Name	Costs of a \$10,000 investment	Costs paid as a percentage of a \$10,000 investment
Class N	\$152	1.52%

### How did the Fund perform during the reporting period?

As the fiscal year began, the market faced the implications of "higher for longer" interest rates. With hopes for rate cuts diminishing, Biotechnology underperformed, though the disruption did offer investors attractive entry points. We are confident in the Fund's investment process and the Healthcare sector's remarkable innovation in diabetes, Alzheimer's, cancer, and other conditions of unmet need. Given the scarcity of capital, the Fund has been overweight those in later development stages, especially in oncology and immunology. We believe the Fund is strategically aligned to leverage the Biotech's anticipated growth. Despite recent underperformance relative to the Fund's benchmark, we believe our focus on companies with high likelihood of clinical and commercial success positions the Fund well for long-term value creation.

### How has the Fund performed over the last ten years?




The Fund's past performance is not a good predictor of how the Fund will perform in the future. The graph and table do not reflect the deduction of taxes that a shareholder would pay on fund distributions or redemption of fund shares. In connection with new SEC Rules on shareholder reporting, the Fund's performance information above is compared with a broad-based benchmark, Bloomberg US 3000 Equal Weight Total Return Index, which represents the overall domestic equity market. In addition, the strategy benchmark, S&P Biotechnology Select Industry Total Return Index, is included as the adviser believes it is more representative of the fund's investment universe.

Fund Statistics	
Net Assets	\$1,439,915,749
Number of Portfolio Holdings	94
Advisory Fee	\$17,506,668
Portfolio Turnover	71%


	1 Year	5 Years	10 Years
Eventide Healthcare & Life Sciences Fund - Class N	-9.76%	2.03%	9.44%
S&P Biotechnology Select Industry Total Return Index	11.93%	1.28%	6.28%
Bloomberg US 3000 Equal Weight Total Return Index	6.75%	7.03%	6.85%

## What did the Fund invest in?

### Industry Weighting (% of net assets)



### Asset Weighting (% of total investments)



### Top 10 Holdings\* (% of net assets)

Holding Name	% of Net Assets
Celldex Therapeutics, Inc.	4.0%
Mirum Pharmaceuticals, Inc.	4.0%
Vaxcyte, Inc.	3.9%
Insmed, Inc.	3.1%
Aura Biosciences, Inc.	3.0%
Guardant Health, Inc.	2.9%
Collegium Pharmaceutical, Inc.	2.9%
Axsome Therapeutics, Inc.	2.8%
Sarepta Therapeutics, Inc.	2.5%
Lexeo Therapeutics, Inc.	2.3%

\* Does not include cash/money market funds/equivalents. Based on percentage of net assets. Holdings can change at any time, are subject to risks discussed in the Fund's prospectus, and should not be considered investment advice.

## Material Fund Changes

This is a summary of certain changes to the Fund since July 1, 2023. For more complete information, you may review the Fund's next prospectus, which we expect to be available by November 1, 2024 at <https://www.eventidefunds.com/prospectus> or upon request at 1-877-771-EVEN (3836). As of January 2024, Dr. Kyle Rasbach is no longer a portfolio manager of the Fund.



## Eventide Healthcare & Life Sciences Fund - Class N (ETNHX)

Annual Shareholder Report - June 30, 2024

## Where can I find additional information about the Fund?

Additional information is available on the Fund's website ( <https://www.eventidefunds.com> ), including its:

- Prospectus
- Financial information
- Holdings
- Proxy voting information